Assess the Application of the E-Value in the Unmeasured Confounder Evaluation of Observational Pharmaceutical Studies

Figure 3

Description of the observational pharmaceutical publications: (a) yearly publication number and (b) proportion of outcomes by disease categories in SOC of MedDRA.

(a)

(b)